It’s Not Always Allo: Decoding Passive vs. Immune Anti-D

Myth: If you detect anti-D in a patient, it must be from alloimmunization.

Among antibodies detected in pretransfusion testing, anti-D is one of the most common and one of the most misunderstood. Often clinicians (and some lab professionals) assume that once anti-D is found, the patient must have been immunized through transfusion or pregnancy. The truth is more nuanced.

Anti-D can be the result of true sensitization to RhD-positive red cells, ie. immune or passive, arising either from prophylactic administration of Rh immune globulin (RhIG) or immune competent B-cells from solid organ transplant. These scenarios yield similar serologic results, yet their clinical implications differ greatly.

How can we distinguish them?

Let’s start with passive anti-D. RhIG is routinely given to RhD-negative pregnant individuals to prevent alloimmunization against a fetus’s RhD-positive RBCs. This prophylaxis, typically at 28 weeks’ gestation and again after delivery, introduces a small amount of low titer (generally <4) IgG anti-D that can persist in the maternal circulation for up to 12 weeks. If an antibody screen is performed during this window and the patient has a history of RhIG, the anti-D detected is likely passive. Alternatively, anti-D can be demonstrated in the plasma of an RhD-negative (or RhD-positive) individual who is the recipient of an RhD-negative organ containing immune competent B-cells making anti-D an entity called the passenger lymphocyte syndrome.*

In contrast, immune anti-D is produced by the patient’s own immune system after exposure to the D antigen (through transfusion of RhD-positive blood or fetomaternal hemorrhage in pregnancy). The immune response can generate anti-D that lasts for years and reappears upon re-exposure.

The laboratory result alone doesn’t always tell the full story. Passive and immune anti-D can both appear as IgG reactive at the IAT phase. The strength of reactivity may offer a clue: passive antibodies tend to be weaker (often 1+ or 2+). But this is not definitive. Some passive anti-D reactions can be surprisingly strong, and some new immune anti-Ds may test weakly, especially early on or as titers wane.

So how do we tell them apart?

Timing is key. Was RhIG given recently? If the history of RhIG is incomplete or unknown, anti-D is no longer detected after ~12 weeks and is likely passive. Antibody titration can help: an anti-D titer >8 or a rising anti-D titer over time suggests active (immune) anti-D. Clinical history is crucial: has the patient had an RhD-positive pregnancy without RhIG? If yes, an immune anti-D is more likely. Additionally, fetal and neonatal testing can provide context in pregnancy. If the fetus lacks the D antigen, any maternal anti-D is unlikely to be from true alloimmunization, although there are exceptions.

Why does it matter?

Mistaking passive for immune anti-D may lead to unnecessary anxiety, mislabeling a patient as “alloimmunized,” and inappropriate management (e.g. withholding future RhIG when it’s actually needed, or increased fetal monitoring for no reason). Conversely, mistaking an immune anti-D for passive could mean missing a truly sensitized patient – potentially resulting in hemolytic disease of the fetus and newborn (HDFN) or transfusion complications down the line.

It’s worth noting that passive anti-D from RhIG can sometimes mask the early development of a true immune anti-D. For example, if RhD-positive fetal cells entered the maternal circulation shortly before RhIG was given, the prophylactic anti-D might temporarily suppress or hide the initial immune response. This is one reason many obstetric protocols recommend administering RhIG as soon as possible (within 72 hours) after a potential exposure – to prevent true sensitization from gaining a foothold.

History, Timing and Context

Ultimately, interpreting anti-D serology isn’t about a single lab result in isolation. It’s about integrating history, timing, and context to protect the patient (and in pregnancy, the baby). No antibody result, especially anti-D, should be viewed without the bigger picture. By carefully distinguishing passive from immune anti-D, and ensuring patients get the right management: RhIG when needed, vigilant monitoring when indicated, and avoidance of unnecessary interventions when the antibody is just a temporary guest.

*More information on the passenger lymphocyte syndrome.